secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001753926-23-000678
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella Pharma Q1 net loss $1.1M; cash $4.0M; Phase 2a LP-10 positive
---------------------------------------------------------------------

- Net loss of ~$1.1M for Q1 2023; cash, equivalents, and marketable securities ~$4.0M as of March 31, 2023.
- Phase 2a trial for LP-10 (hemorrhagic cystitis) showed positive safety and efficacy top line results; Type B FDA meeting planned in coming months.
- Established Scientific Advisory Board for LP-310 (oral lichen planus) with five experts in oral medicine.
- Entered manufacturing collaboration with Cook MyoSite to support LP-10 IND application.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000678/0001753926-23-000678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392623000678/g083547_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-23-000678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer